Aducanumab - Neurimmune Therapeutics
At a glance
- Drug Originator Neurimmune Therapeutics; University of Zurich
- Drug Class Antibodies; Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
- USA Patent Applicants BIOGEN INC
- USA Patents 9
- BLAs 1
- International Patents 121
Disclaimer